Current Report Filing (8-k)
March 02 2017 - 04:15PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 2, 2017
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
1-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code: (301) 417-4364
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 - Results of Operations and
Financial Condition.
On March 2, 2017, Synthetic Biologics,
Inc., a Nevada corporation, (the “Registrant") issued the attached press release that included financial information
for the year ended December 31, 2016. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information
contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any
of the Registrant’s registration statements or other filings with the Commission.
Item 9.01 - Financial Statements and Exhibits.
|
Exhibit 99.1
|
Press Release issued by Synthetic Biologics, Inc. dated
March 2, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SYNTHETIC BIOLOGICS, INC.
|
|
|
Date: March 2, 2017
|
By:
|
/s/ Steven A. Shallcross
|
|
Name:
|
Steven A. Shallcross
|
|
Title:
|
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit No.
|
Exhibits.
|
99.1
|
Press Release issued by Synthetic Biologics, Inc. dated March 2, 2017.
|
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Mar 2023 to Mar 2024